| 000 | 01598 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250517184529.0 | ||
| 264 | 0 | _c20180814 | |
| 008 | 201808s 0 0 eng d | ||
| 022 | _a1476-5381 | ||
| 024 | 7 |
_a10.1111/bph.14095 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aWang, Weijun | |
| 245 | 0 | 0 |
_aTauroursodeoxycholic acid inhibits intestinal inflammation and barrier disruption in mice with non-alcoholic fatty liver disease. _h[electronic resource] |
| 260 |
_bBritish journal of pharmacology _c02 2018 |
||
| 300 |
_a469-484 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 | _aCaco-2 Cells |
| 650 | 0 | 4 |
_aDiet, High-Fat _xadverse effects |
| 650 | 0 | 4 |
_aGastrointestinal Microbiome _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIntestine, Small _xdrug effects |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 | _aMice, Inbred C57BL |
| 650 | 0 | 4 |
_aNon-alcoholic Fatty Liver Disease _xdrug therapy |
| 650 | 0 | 4 | _aRandom Allocation |
| 650 | 0 | 4 |
_aTaurochenodeoxycholic Acid _xpharmacology |
| 700 | 1 | _aZhao, Jinfang | |
| 700 | 1 | _aGui, Wenfang | |
| 700 | 1 | _aSun, Dan | |
| 700 | 1 | _aDai, Haijiang | |
| 700 | 1 | _aXiao, Li | |
| 700 | 1 | _aChu, Huikuan | |
| 700 | 1 | _aDu, Fan | |
| 700 | 1 | _aZhu, Qingjing | |
| 700 | 1 | _aSchnabl, Bernd | |
| 700 | 1 | _aHuang, Kai | |
| 700 | 1 | _aYang, Ling | |
| 700 | 1 | _aHou, Xiaohua | |
| 773 | 0 |
_tBritish journal of pharmacology _gvol. 175 _gno. 3 _gp. 469-484 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/bph.14095 _zAvailable from publisher's website |
| 999 |
_c27789927 _d27789927 |
||